Research programme: MM 151 companion diagnostic - Merrimack Pharmaceuticals
Latest Information Update: 02 May 2014
At a glance
- Originator Merrimack Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 03 Apr 2014 Preclinical trials in Solid tumours (diagnosis) in USA before April 2014 (unspecified route)